NVTA - Earnings call transcript Q3 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by. My name is Brent and I will be your Conference Operator today. At this time, I would like to welcome everyone to the Invitae, third quarter 2021 financial results conference call. All lines have been placed on mute to prevent any background noise. After the speaker’s remarks, we will have a question-and-answer session. Instructions]. [Operator like call now to turn to would over the Ms. I please begin. Hadsock, Amy

Amy Hadsock

Thank Thank Call. afternoon, us good you, and Operator, everyone. Third XXXX for Quarter you Financial Results our joining for

CEO, Digital now Joining are founder Rakesh Officer We're joined Chief of Group, by us today Patel, NVTA serving of Invitae's Oncology Wen, leaders Medical our [Indiscernible] Sean our a also within today two as Mitchelle our of and Health. George, Oncology, CFO. and Roxi Medneon President Dr. and

Factors for date current speak differ on statements to recent to outlook. expectations. begin, services, could statements pipeline, are predict materially of the information Reform demand refer we product actual of We additional any remind titled future opportunities, the acquire, that Act. XX-Q, our including and we Before restructurings, our therefore legal and products forward-looking our additional from strategy, market most and as plans investments, assume, the for or results Harbor like other I'd Company the you forward-looking business our Securities to on Risk on about and that our of accurately particular, results, plans investments future various to constitute only businesses within settlements. make services timing, we we It's our infrastructure integrate and These and for statements you this our remarks actual services demand could in the factors don't of from in of manage Private prospects, materially conclude reimbursement results financial performance those difficult to stated provisions not that and Litigation among Statements that meaning hereof. operating call Safe focus These cause differ things business that historical, acquisitions, and their operations. our section

We available, which warrants. tax per of call from encourage received over I'll expense marketing, review acquisition-related including you cash press research non-GAAP exercises and Principles To our We non-GAAP accordance acquired which U.S. non-GAAP well assets, as expense. are GAAP Net, in to compensation, or fair the applicable applicable value and post-combination that, from supplement the we turn available acquisition-related the changes as cash general cash Company's as may and and non-GAAP revenue, bonus marketable development, payments appendix profit, among include with loss the amortization and several We debt, received related share we acquisition-related have slide and loss as and other acceleration to assets grant the for reconciliations, burn. adjustments consideration and our and results consolidated includes you monitor metrics items, measures administrative business the operating our exclude prepared and other to liabilities, of and exclude With deck. Accounting to consider and cost key of or certain net income quarter. as call, non-GAAP you intangible the net to from expense release results, including in equity statements, measures. listen income securities, today's the conference selling and release our earnings Accepted press to growth connection in as the in in our financing gross of in combinations, Generally financial cash burn encourage benefits. equity stock-based Sean. As financial on GAAP, the with of commentary operating of the well contingent

Sean George

Amy. you, Thank

dashboard be towards our for using a our set metrics outlining the as model's to business of I started, call, Roxi want emphasize will get a key be we that business will we of end going success. Before forward

As relevant areas, more to other provide in we've and platform working those smarter, addition been developed expands our to into sectors. life business measures science services our testing used from is traditionally in

call by on considered, the period, to quarter, and year's over this third serve number last comfortably which X% rely we'll over forward. QX refer several going patients up To keep growth with of this all -- year's year's XX% within quarter. headline things dashboard our grew we quarter, on longer-term will heavily us We new last revenue targets that about and over revenue than grew second those times growth more XX%

slowdown and charts, was we but During view, much growth for of the how top-line a difficult any of year-over-year some lasting some with well have are individuals, arrive, weeks, months for ago, our for toward data families, summer reality even diseases advent Invitae. family It that can ageing. early minimized we're medicine management, that the much managed COVID be now pronounced planning, remainder unique guidance be But accelerated this storing, years. bit The as condition And attracting, unusual tapping seasonality seeing in a the and information revenue of health in be years aside on our and analysis, was the recent can even be healthcare. or and a health in testing demand they we benefits but derived Reflecting and the year's that And persist. wellness, was more is decades. how of risk that impacts genetic our shift that here, across with staved the platform midst rendered understanding disease on only to for cautious couple can is fundamental can than view will fluctuation, demonstrates continued Since long-term not is - XX short-term often. see, years of therefore, progress into when use in the see when to being the a the medicine, but a future case only longer view, off? understood and genetic information related. the typically meeting of in populations. and a we're year how you unmet In the from and those pickup the experience will is immense you the determine seasonality, We're genomic and as through past chronic many takeaway with of in at something of time health-related

timeline is While identify for ability are size. and to fundamental make large genetically is diagnose areas be In will rapidly that for preventive the can is at disease. even can expanding services X stages the create and outright individuals treatment, these each BioPharma increasing full next we created to into of from transforming information disease, ability the standard that focus to We of markets X that investment standard the treat quickly the healthcare. those guide our drivers of of system or the monitor in coming years durable that that treatment targeted durable and need that future the of primary care for large multiple the and adoption markets prevent to targeted life. reality large, risk of of all Furthermore, for The value X are be long, that believe and those of tailwind in those life-cycle deliver detect coming the the immense. onset the over use better will believe Much [Indiscernible] today's measures Company very earlier, to of pipelines throughout or diseases be therapies. success far the of will that is

this and Some information. utility to improvement is better outcomes understanding a of costs coming from using of the

and this to those a perceptions better their changing from attitudes growing role that of the engagement volumes coming coming for much is the is it from is paying medicine. And it. of shift patient of evidence in from Some about and shift healthcare the exponentially own

patients believe a missed role heritable example a for rapidly, in of and example, how testing X/X the kept that the nothing trained and it. use about narrow died we the provide oncology, management cardiovascular them condition. an race. life could as informed and father little suspected XX-year-old and stage, we've large help clinically are rare happened real-world stages which and And network of study Her their American of a the business week by being few the than how most mile been their be ago. network, genetic health, risk to that platform through testing That ongoing A can of Heart of along patient disease to broad more our eight out pediatric, I prevent screening, -- adding a that Today, for progress of steps I next article mentioned meeting, as data as but addition, Thankfully, to for spectators such alive that information information generate that or at escape. Association growth? to in to oncology. data found as a about our will that dropped minutes recently for connections the a every note generated own to information our XX-month adding and partner X of that new and reproductive can change, call health, disease, such genetic for a approach. step way. in pavement can individual In marathoner, old having of a along Washington that utilizes will clinical projected read our as as narrower capabilities brief a disease a XX cardiovascular platform at by medically the of measured have to needed therapy be out in see cardiopulmonary really patient For selection, the used each or market give data areas will over at We variance as new insight presented in customers effective front building a move connections more more the ago, to and that for a condition put the heart cardiovascular business hands. son, to using fact, we decisions Post well make about that mom identified as were the well be relevant help implications today broken genetic would've X XX% part to be and the can assessment, and formula our disease Which at platform prevention, the we monitoring. future, patient more could

before, I'm sign to be we that map journey later where call, drivers key using will overall for able that are progress out the hoping I we coming. to posts, are will Roxi and will importantly everyone from we measure our future to today the using business metrics these very be financial in is the our the lay model. mentioned and As as against certain

the of calls. month just it's to like business. Given given on give year, going near-term is Invitae, how to our on at of all But into quarterly our the more it not a much little we'd drivers least possible any cover insight at

coming customers him Vishal asked more I've So we'll on revenue from Chief some of from in invited of relevance benefit each to also our the year. today. the over on Medical platform, you than coming which to potential join Medneon and which physician be first healthcare clarity an entrepreneur, I've ecosystem. co-founding Invitae our acquired future. of the since how Rakesh spend dovetail an margin was Sikri Doctor revenue years. becoming areas Vishal. before near is our little that our platform we'll oncologist that Digital Oncology those studies patients, quarter, hopeful Officer and practicing month, with group walk and leads for of hand and is quarter physicians, and the Health to us clinical outline health underscores the time it important products product our our XX digital will more I'll our Patel, for focus trial second products especially additional on years in to plans a Rak health, This will to this growth families, growth. Rak and in the activity broader and to digital platform, provide risk the Oncology one online drivers key services business, remission

Vishal Sikri

for road oncology, part the Sean. In includes you, product an that of the support growth to impressive different benefits which pologenic risk to have year active provide combination multitude a with innovative years, testing 'XX map, expanded update patient's in offerings, journey. NVTA horizon. to Invitae Germline years, this tests a tests germline germline Thank been continue I XXXX. XXXX. expect testing portfolio for expand leader vibrant testing additions where been RNA score through are of tests into we clinical is [Indiscernible], germline new given plan have pipeline the on the in added has of of acquired These we an and a and verifying showed will platform. across an the third-party our a with growth our on the in somatic category to offering And germline Company integration a DNA ArcherDX and and we one risk studies, somatic recent defining treatment. and course the combining of Invitae testing only on combining developing best and and testing tests the

an biomarker use-only clinicians. front include to include offerings demand research plan our kit important this also testing instability, as the mutation also selection. offerings DNA-based therapy tumor our will from On RUO, the year. a microsatellite growing end to for burden TMB, expanded MSI, or for RUO by known we launch expanding addressing That of We're or offering

on of In innovate plan to up our the derived clinical is monitoring, coming being XXXX, tests continue our developed cancer stood offerings lab PCM, a centralized to front we which offerings laboratory for with tumor personalized year. series the in launch We test.

stratified a year, While a tests and market. we'll initial forward in offerings expand as to trade therapy test -- we commercial but as factors. offering informed IP us to important giving to be we somatic DNA, This PCM the offering, using of monitor the view stand advantage brand include that pan-cancer lung emerging accuracy we to MRD in plan as our a centralize in what proteins. pushing comprehensive will alternate or capability research we and therapy RNA, is LVT detect recurrence this up be cancer, our Later selection similar other our and believe names of body by and the Archer selection is to due a offering, demonstrate distinct

off detection cancer development Finally, assay to work in on for our plan purposes. an XXXX, we kick screening early

-centralized will particularly and today. IVD testing diagnostics front EU de On to and where parts therapy for growing, to customer genomic blood moving in reimbursement, competitors are towards kit the we're cancer where EU, beachheads marked invitro no at towards which of CE is product the or service genomic IVD IVD testing higher Asia. regional we're XXXX, plan launch first us our first profile base of our a facility satisfying expand the is our markets creating for centers. demand select and LiquidPllex technology and academic solutions samples claims solid tests These will for and FusionPlex adoption. European in Both products running in Outside countries major submitting This enable will to tests. tests XXXX. DX facilities. the tumors any our help with and accurately selection our step their Europe of demand QX therefore, capabilities, get in local for pent-up DX sequencing and among additional include leading Japan test, solutions increase labs allow in will We It

in heavily our decentralized. countries strong With especially tests, IVD the U.S., testing of we where outside launch expect of the our products adoption is

our we these our continue with launching the of in the commercial the past, the better the regulators a requirements ongoing Europe anticipate tests. of map approach tests these the U.S. we collaboration better PCM for product for U.S. a detection. to highlight is MRD well types. we well including globe is in level, work KOLs customers including for in of multiple blossoming, our perspective MRD met in the will have with And a of project, PCM of continue hereditary assessment. making for conclude to be lead fact for It the assay surveillance intercept Asia, current cancer understand I test data Medicine pack medicine with floor testing to a demonstrated This trials. the FDA, wealth important XXXX, from IVD data data the the types. hereditary portfolio road Personalized -guided importance a the as are the is launch our ICAP a provider new will and driving as studies. experience to end tumor signal studies, products the will Rak. our publications value-rich best being investments the additional profiling risk us trial, IVD Maria. studies use publications, and use be forward intend early of as our is academic blood to resources to XXXX. and strategy will to and as we MSK, additional Cancer of initial as Meanwhile, PCM stratification and means of readouts to the as and good our individual continue well path kits XXXX, next academic our and products, Maria year in of with by expect tool working Company decentralized Invitae across Rakesh we support importance field, for our hand underscore and we're PCM In of our with a products the of an as feedback for clinical month. on Research, outcomes. we Altogether, pushing and retrospective intercept, approval In collaborators our highlighting Archer and Friends avoided types. including across partner substantial as and health the response projects, from patient patient PCM a integrates Invitae XXXX, Dr. for and consortium, multiple perspective highlighting and across study to platform. from Coalition. of in our journey, which expected our we XX FDA high testing recurrence the met PCM in by we -- practices case therapy how in has have will On But including to including we and monitoring HRD the tumor TRACERx Based digital end-to-end Maria an cancer cancer MassGen for expanded a Then XXXX. planned value by study, multiple who believe and launches the we initiated data a publications, for cancer stands participation this with personalized finalize Patel, studies in that here through partners, trial believe those derived our planned global I we the walk tumor now presentations including including with from product multi-tumor In expanded our furthering excellent community germline support tool, trials IVD to in While and readout

Rakesh Patel

you they're and multiple molecular Vishal. clinical achieve The lifetime. precision a involves testing practice emerging after ever treated across they're Thank before oncology applications remission. to patient's well and diagnose From of

First diagnosis of all, utilized for cancer of routinely analysis syndromes. mutation hereditary is now

of For patient’s cancer become treatment, tumor monitoring Tumors patient adjust is needed. over integral to into patients, may primary the resistance an a mutations therapy shed able early already possible the evolve detect mutations their during diagnosed fragments and of the time biomarker part almost therapy. significantly bloodstream. critical has detect of be always makeup molecular as to profile testing to Since as tumor when actionable

treatment molecular to biopsy when therapy, It can quality promise used to recurrence of diagnosis, at testing providers as informed, as for Invitae for not can to non-invasive treatment practitioner's oncology cancer We're disease. decision-making. sample detection, will pathways, decision the ray adjuvant keeps used response a and sufficient. an turn, patient's based cancer empowers for liquid the and preventive DNA, critical early the We is testing or the neoadjuvant or or journey. complex monitor provide likelihood Digital facilitate option holds is relapse detection a be platform most It or From capabilities that share dense cancer be a guide every rapidly believe is an and tissue quantity of and not with and just of expanding Health building measures the after So-called knowledge a is end-to-end the therapy, predict an tissue alternative resistance. can markers. stage of also great that an perspective, platform in biopsy, circulating that of critical or analysis patient

testing cancer not risk is one-time in genetic Importantly, a event. assessment

is individual’s robust or multiple of a of lifetime, their of precision remains in area. each patient-engagement As expertise, patients to but effective cancer we an decision way it are not providers benefit a in single context, a treatment an disease with treat updated having preventing after genetic and change both the -- caught guidelines plan does therapies. to from that molecular have assessment, early a usually now over cancer a a is a develop capability individual when clinical profiling cancer is one's before leveraging early with There's only before and get The trusted, for available direct predictive a paramount. providers the medical is cancer is genetic frequently is risk most focusing goal to diagnosis, information disease history may unique patient amount never therapies or there's tests, on of targeted family and diagnosis. oncology Once detection a of tools all types diagnosed, and novel tumors developed relocate population changing together. cancer Since And challenging. key after large one. better and multi-disciplinary change keeping are rapidly diagnosed is in Outcomes core that health, genetic support analytics focus over ideally time accurate for a

re - as monitor staying the just patient management bring allows plan. assessment, important early treatment Medneon. [Indiscernible], of is outcomes platform sub-visual providers Following personalizing the cancer to in YouScript, to order expanding retesting, multi-disciplinary insights The and health treatment, to for situation along AI secure capability, From will patient to medical which In mission to citizen potential point-of-care connected and remission necessity risk Board records development of practice. once the to extended with portfolio. to most a personalized identify frictionless enacted burden, therapy many intervention again chronic into with a Tumor of clinical turning a for Medication Digital collection expectancy. terminal guidance, life patient durable disease into for wallet effect, patient strategy with support health Virtual several genetics by medical based our and through engagement modules with NVTA management testing with mainstream our boast to education

will longitudinal, We for platform support coordinated data Sean. care Thank clinical a personalized seamless provider integrated active, coupled stakeholders. patient engagement, strategy. an provide capabilities and you, Leveraging decision and for real-world tech-enabled with and to workflows Back all efficient you. clinical

Sean George

forward Rock to for you, thank discovery and months the platform, we Thank looking build what active the for tests you, most patients necessary the patients, introduce and important research services We're performance under believe robust effort anywhere. ahead for datasets be drive for scale new Vishal. to oncology we new and and those will financial bring and as and available

for cover the the Before discuss drivers Roxi. business Wen to I'll Roxi over key and the go metrics results Q&A, financial call to to important hand NVTA. and we

Roxi Wen

international XXXX year. our and quarter Internationally, thank XX% volumes all of second and increase quarter businesses up the ASPs of you saw to volume from and health Sean, QX billable total ahead and Thanks, third of X% third to this XXXX, of we us Billable approximately quarter, women's sequentially was $XXX of the the in XXXX. XX% over second ESP mix the quarter. This we Overall, products. the testing quarter in week, sales, from that U.S. to $XXX volume in trended from flex of quarter of today. growth of the compared for other X% in the down slightly lower which have were represented $XXX third joining

benefit detailed Looking did and in through for this MRD and for LDT rates. non-GAAP XXXX, easier review to IVD [Indiscernible] business understand from of and to reconciliation press quarters, have which today's it reimbursement to by sets financials metrics expect comparison of providing ahead of non-GAAP of prior deck. the to investors back testing is notice we a higher financials for numbers. selection, to included launch at of testing I the We release urge broader two therapy our and the allow our the AFP monitoring slide in All

remainder of members burn. the we'll non-GAAP For including the discuss cash call,

Our and number was to by operations second inventory total a $XX overall the non-GAAP $XXX in Oncology XX%, gross non-GAAP profit margin the unit of quarter billable revenue continuing progress the the improvement business. the gross due non-GAAP improved of management first to translate third as of efficiencies defined $XXX gross the margin XX%. in in the cost to per with in slight cost quarter, divided units, our in over of Non-GAAP million QX which a quarter, a from

management. We expected in expansion cycle map and pricing, execute road positivity, continue down, progress cost as to our revenue we cost margin product variable

down the quarter Moving million expenses in non-GAAP $XXX.X million second P&L, quarter. the operating $XXX.X was in the third as compared to

acquired businesses. quarter from include The costs newly expenses operating third

we of the is expected in come in call, the down rate half second of to growth our year. QX stated on As spending the

portfolio return investment goal be business to and level. on to total at this scale committed continue as We the manage we the

year-over-year approximately from which the business as by We such up acquired sequentially. year-over-year, the driven by down continue to invest and our Including problem XXX% as as ArcherDX, was collaboration. costs research headcount The costs well by million following Pac but areas, compensation, Bio $X.X growth development, in and was in businesses, our stock-based mostly

mostly flat our sequentially, the legal quarter, increased to investment XX% marketing up million was over in high-growth year-over-year In rate and due the expenses expenses G&A support capabilities. second over higher $X -- addition, $X but XXXX. ERP a and by selling to

This and areas. the Looking in benefiting key rate planning stabilized as the and growth initiatives. the OpEx forward, declining as of even revenue down we're highest XXXX, various margin from improvement of into fourth continued non-GAAP for operating should in percent the mark investment levels top-line slowed quarter a expenses begin to annual or growth year

the Moving and to million the restricted June to billion quarter, fund XXth. as cash was our acquisition. for equivalents, XXth, at finance $XXX marketable September securities paid third cash, totaled and in including $X.XX cash position, cash Cash clause compared $X.XX billion

Approximately certain breakdown third the from for diagnostics. quarter third [Indiscernible] quarter as groups would quarter, our follows: and the of and and from management, reproductive was million. Approximately from $XXX includes growth platform years. [Indiscernible] This including program. all the revenue million. highly the germline four and [Indiscernible], covering a year-over-year by Revenue from data-as-a-service, and been generated health newborn nicely million our the $XX testing, from The ambitious. the Data million Approximately expenses, business was $XX BioPharma analytics, neuron, data $XX take [Indiscernible] across other rare We quarter related testing out-of-patient the revenue million $XXX and tests. in XXXX. diseases areas is cardio, companion and screening. $XX product from complex, women's and XX% metabolic and acquisitions model other Excluding million in -- and offerings, third quarter the revenue increase therapy in-patient, two third past differentiated, of oncology increased selections, approximately including in have

shortly fundamentals taking as grow your tour, I of our the support to listening help and the a initial We to appreciate understand our after joined scale. of our better the of also number many and business to desire business. the visibility continue into During are team, we you expressed steps

our revenue of each categories. provide First to analysis trend to we plan continue with

calls Second, business will leaders our and rock expert subject quarterly our and today. be business provide half deeper the insights joining Vishal matter placements, our into to as

available We these categories for internally ability operational metrics visibility to returns-on-investment describe of going patient our M&A our to accurately systems, and pharmaceutical a based per services the data we'll on business commercial our future, points Revenue or and forward, set through hospital our developed growth as business and and of for our revenue be include population recurring metrics patients partners, key the in sharing. testing [Indiscernible] annual significance Third, expansion of ramps patient access clinics, up. for selected providing clear and These and business. activities. of their

of continue but of New freshness part over trajectories developed to X strategic measured new of leverage. the also by measure connect ability revenue portfolio. of our the of least, category expand will margins investment years. vitality through the productivity. margins products decisions variable not This and contribution cost We'll last Last gross to or acquired the by

scale metric, cash as of addition a percent operating to and standard to flow the revenue improvement. In show to we plan report expenses operating

by focus Our this know not is quarter. category to dashboard, every goes important both success it area that needs useful in an that attention be future on is It a objective net will time cash progress, signal operating If measured flow. is will by. to be increasing as every to

intend and Our provide roll on objective more offer transparency we perspective the forward. out as within to continue end this move of to people. maintain framework We at balanced these and performance in update these complex, our sharing genetics a into as metrics our fast-changing bring the a to business consistent, to journey to year is we [Indiscernible] the quarterly

of million. $XXX revenue led we $XXX between for revenue Back provided year, QX us of the to for As adjust of be range million year greater projection a to and a seasonality in this were our to result The between XXXX. Sean. August range slightly and guidance the growth $XXX year, and $XXX expected you guidance this to to more the XX% between and XX% to has for cautious than

Sean George

shown view effort evolution our medicine. an We've in we model of of the this Thank ramp business see you, to describe genomic global Roxi. long how

Our emergence progress global to and and the era, faster. data their scale platform up patients’ a be needs span, the more throughout genomics therapies genetic to diagnose can addressing information services the and of correctly, progress life market bring shared on curve demonstrate patients into in earlier network our where

we and we've new believe genetic from can the of the their can capabilities platform. we supported the our on partners information test our The continuing built in an and we patients We that, way more evidence by behalf, digital integrated technical with them. products the for extensive and more delivered, real acquire out more our these network. staff integrated that building investment to capabilities. patients add content, world reporting, in the tech-enabled provide an services. an continue And can The service we continue the developed, interpretation, to ingest more connected the best of and landscape of data, to turn With healthcare development that next across do are our that Operator cover customer or workflow, personalized combined can we call of experience portfolio the we'll and network more ecosystem And for services improved Q&A. over now insights, to other of through enhance our pipeline, many years, platform steps include capabilities. processing, analytics, in Over customer and

Operator

Q&A a [Operator compile pause the to moment for Instructions] keypad. We'll roster.

Your first question comes Cowen with and Brennan from the line of Dan Company.

Your line is open.

Daniel Brennan

fourth and Great. the ability that baked supply the quarter. more going Thank issues guess near-term, your maybe obviously on that questions, with Can give were you meet the What's of in of us kind it's there question I just sense just chain a the -- fourth-quarter quarter? into you. impacted pacing guys. Thanks [Indiscernible] to persist for customer it taking COVID, with first needs? seasonality and made any to in

Sean George

Thanks, real pickup pick except on Dan. it. QX Typically comment appreciate up. from to the there's I QX. typical Yes. seasonality a No QX

that. ascertain picked while a typically stated, of that summer it than little up that there's just in But off see we coming seeing said the unusual in With from being indeed baked now about or that of as QX little rest bit difficult And of we [Indiscernible] two a are kind as there, coming us. year. see. end it's circumspect it's were so the into seasonality, a later We off definitely QX to don't we some anything week front from COVID we're a of of of

not new for sure that. there's anything As Roxi supply-chain, the I'm if on

Roxi Wen

pretty it's quarters. previous the think with I consistent No,

Daniel Brennan

I'll yes, -- going for ask to sorry. across of I kind ahead. -- then And go was

Sean George

Go Dan. ahead,

Daniel Brennan

Natural.

by more oncology guide kind should back long-term think sense when we as but within Invitae, aspirations points? between in out big about look the maybe health, growth the mainly if Really just impacted businesses acutely be stepping ask any context health, women's could and fit the segment, to sense? women's than on give you and we I how others, going then of of obviously across the of Were we picture Gulf other those know I'm in us you segments. two. your how Sorry. any the don't some for four thinking oncology about

Roxi Wen

at Yeah, going forward and again across-the-board consistent from as we experienced. longer traffic look see categories. I end-market [Indiscernible] revenue QX those that in issues particular really product X guidance in goal-forward from we like seasonality growth pretty we look In revenue a had at a we QX, indication we would revenue area perspective. these corresponded And perspective, areas that didn't

in in will to the of platform patients come the of We will and access not trend. see forward, as metrics, the change That the also points understand all level also categories. in patient, some to measure our this number the well key do at And of across -- revenue introduce that a be and how quarter be data and success you platform metrics, per as to we predict concept to growth. help started account some going

Daniel Brennan

one maybe final then And one.

on there's we on to I'm what advanced, lot didn't from all wondering for in the anything on track, therapy exactly some previously just a of color out products timing? -- products all is up cancer communicated put super coming maybe You anything there new is timing, that. that -- everything the you timing about just of terms slides close MRD, as across selection the not the and

Sean George

FDA two -- FDA the I'll different stratified as will Nothing that we've application, start talked and or is and actually let out, now Vishal earlier with about three that discussions new. the we public invisible laid progress. had The finish.

but So regional really today. launches, news, more the different kit We review Vishal's detail, to put that but behind approvals. reflected that, is in nothing new. little Else tried old a the

But that is part in-market new we which that Vishal, it I -- anything commercially. end monitoring our about. personalized for forward materially the testing. next impact our We for Vishal for for expect we the year, spoke road -- and to now there. even One impact necessarily then year, cancer this when map we of year. is Looks do nothing the MRD, revenue revenue as hit missed? not call main speak, That of events this

Vishal Sikri

I you track. it. think We're captured No, on

Daniel Brennan

Okay. All much. you very guys. right Great. Thank

Operator

of Savant Morgan Stanley. question comes Your with next from Tejas the line

Your line is open.

Tejas Savant

Hey, guys. Good evening.

guide. numbers do on you -- absent last baking had the go in mentioned Sean, I I the we time earlier had in and uncertainty want you back spoken, question into the to Delta So know to impact.

by now about to expecting in were the midpoint million. or then lowered the come you've $XX above You high-end. at Since

was you just you help weeks weakness back terms for recovery metered in to ramp are it X normalized of here volumes the as very head 'XX? So And a anticipated? V-shape can saw much the we essentially you X you bridge there? calling into back, build concentrated or greater than or mean, bounce had us more was I August that perhaps and it a

Sean George

the half people do there's know to much we really typical all The because locations, is, to X seasonality had and -- -- categories a gave there, ascribe an color growth, hard et I'd up give look Made a that. seasonality weeks I And cetera. pause or just hang saw year. from before, going saw In On a obviously so to a end team, Yes, to We product as day at it's loss estimate volume can verses formation, X is in COVID. on like it signal. tease a categories thing last which offices you geographical we can relative mentioned, came usually though, signature data our calls volume impact U.S. offices clearly both to we later the or of equally, new Again, Roxi strong that's as week, of say the of hit the were call, out. it checking did it week see ex-U.S. it sales seasonality, not absolutely. and a either -- detail we the it being And good the loss how it persisted that than also, COVID early we signal, or we two and it. -- not with little to also that and it's into see And anything and to us some a see impact. really -- seasonality more looks don't COVID account the

can then to QX, we -- quarter, enter given and As view were where the is adjust circumspect end as this going where take just we the at a our to the of year. view look we

with signs only bit get to the thing in We industry-leading perform quarter. we our continue different do But were we range a last growth. than -- at that on recovery, are seasonally reflects QX our just that relatively expected dent number delivered. it, and of of see spot annual a We within that

Tejas Savant

like cancer, there you'd then a it. detection And called mentioned of 'XX? the 'XX. then now basis? go-forward been front growth. How early incremental outpacing a It's where one’s that trend assay Got of business sort any a forward of for to you U.S. strengths to quarters of pockets on expect that international couple any couple color to of on highlight? you And looking development particular versus the out you've And do there timeline

Sean George

Yeah.

clients. area. a There where it's best also thing is the country ex-U.S. walked particularly centralize of market country kits when by of a and or specific therapy obviously there service pent-up the led a the Vishal - approvals through by that's the ex-U.S. based going demand those regionally and they be U.S. to lot all serve -- high-growth of So monitoring, to even for isn't selection

we So that we're to -- expect contribute more.

could payers identification all continue more the to the do and other etc. thing clinical U.S. also happy -- better. wherever, The And find us continue to the testing allow it more reimbursement, more regions. to does those but expect our we would put outside look patients U.S. in with is than programs, they the to the They're patient Medicare traditional reach business more momentum global pharma-sponsored they

notably the as think continue ex-U.S. important story. those that support an are continue drivers We part to growth that to will of We'll there. the So our revenue. see

-- our will oncology not at bio of from and on going trials work 'XX. next We're monitoring, the we that on them. and year to scenario for really the the in action product of to I be be a assessment, taking our the question detection our we're what in patients. out through like our and clear, in I finish own -- don't portfolio is therapy selection, detection looking start think doing and your validations, end certainly early course, well. look second to early have Most technologies just for both also action own our currently launch as But was of want calling risk

Tejas Savant

'XX the there? about expectations then offset hereditary one Got heading for me. the it. volume your final are versus as what the cancer on testing piece we And in of business, the light price Sean, into cuts PAMA one of think

Sean George

a one. good It's

It's overall like on but to less PAMA the that just going going what a a the be. a going We'll but it'll forward probably of used of there year, why. will revenue, But than I be business, hereditary full lot say Without cancer to going affect not to think guess immateriality. the that of our think the business. becoming think context to important is work different after in it's than details, in impact to that; -- I years. So they all And won't I overall decline do will cancer less certainly impact. it an cancer be be. little I and will next little less revenue past be our material try to some going be -- more won't the it be to oncology exactly it's to don't impact. of wouldn't immaterial it's I point

and across-the-board that be won't we we're still as working speak. it details the mentioned, on I As on

Tejas Savant

Got it. Very helpful. Thank you.

Sean George

Thanks.

Operator

question comes next Your from Tycho Morgan. Peterson of the with line JP

open. is line Your

Tycho Peterson

coming of for out you're said about out per of year third Coming kind Hey, thanks. think XX.X you margins? Can you gross quarter. help XQ, us to XX XX the now at

the and So margins how think do after forward? about going fourth gross quarter we

Sean George

investment a there a fact our in change It of rates thing faster, perhaps There buckets. pricing. the biggest more we less as The on the -- reproductive there and mix different volume on growth, some X where we has to needle Yeah, our towards much new a to for bit. gross And down taking out, NFPS say market of etc., inventory is growing but moved little years bit from volumes, not X want X, couple focused be fundamental last some more stuff ago. through products, is that on carrier. in COGS still creation, acquisitions. more no, are take been hasn't revenue But as of that more and take There pulled particular, is margins. a getting I'd in years, over years, are also that -- share we relative is price market drags growing is growth and

want see out good will, margin confident be. price back that improvement. scale. other our And to just measured old-fashioned so And with of exactly business of and to we And know will quarter series work in that business laid metrics. between products not start where key said, Roxi on showing target are with our then economies against higher volume we'll that that our every people will COGS people own we're We're -- dashboard, new as XX% we be progress as higher

Tycho Peterson

to -- I you're around I just going or everybody us mean next OpEx, 'XX year studies [Indiscernible] you're else those on screening? a to lines, -- thinking you are you how overall? need not able do spend to I OpEx are to do magnitude on give And rough sense yet, for know as think along you able think but for spend to how screening, about guess of you about you are XX,XXX-patient like you and about to do start studies the

Sean George

-- we is if reverse. first and Let's will you are, then where Roxi and then do we the screen why to Vishal that on year, speak -- now don't next

Vishal Sikri

that's to need It's there. lot Roxi? do The looking will to or on area. do that here to at like screening this buy see, in necessarily we need as really different our to avenues in in XX,XXX area? build become studies Sean a mentioned, successful that. XXXX or now we to we point. side, something clear be do what invest goal at right this anything this we're not at And patient we the On multiple do So is of what

Roxi Wen

front, but growth best OpEx or of that the the versa. on we're we're long-term driving as the that short-term very as facility, focused the well not to on On between Sheet trade not across Balance our strength yet, guiding balance vice long-term, investments

we've business also balance the continue keep of early and effectiveness eye the a strategic returns the some signals long-term of of We'll in keen on focused very our and said, initiatives on has those been and flow investments. is That have objectives. to identify enough be and being a both that level on. So doing, enough invest some drivers very something we're to OPEX our and to achieve our are investments business levers scaled large to have drivers, us focused to operating to focus -- for cash revenue that in

a it's to to and areas the And year operating say long growth so should improvement you for starting expect there continue grow sure. way investments leverage and key QX in should OpEx in some next from from see

Tycho Peterson

me one curious of revenues from acquisition. rough out how if last I'm on think helpful. That's the just business. you can sense you synergies just about the us with and And from never give rest citizen, broke you any then the

Sean George

The middle kind -- it. as to the citizen that will have line I revenue era out; more on with that rapidly alone. buckets business services. hitting a our important it's go revenue, a nicely of really it's services. calling growing model than The there, growth is revenue data, platform, our data, lot other key in assets a to of of that last the quarters And that's data of with with But view in that do feel part said, will out citizen we not enough, fits broke our analysis other analysis part these pointed small important, our be and that this come. good out of a years our really story. we We're other as quarter, set And what essentially revenue data services, our and from

Tycho Peterson

you. Thank Okay.

Sean George

Yes.

Operator

of Your question next with the Sykes Sachs. comes Matt Goldman from line

Your line is open.

Matthew Sykes

kind chart let Hi evolution one the at the chart big M&A usually for towards my and it me perspective, with on looking Sean, we where the slide last or going And strategy. more rationalized M&A you'll of organic show you where forward the attractive more and thanks makes just everybody that comments certain that just expect the and -- to are investments here for taking shift then pause on a coupling are was picture, still bit still, come questions. part first on sense related you I'm your examine opportunities wondering up of if and a the a an business, they degree, a them. spend should is maybe from of

move Just wonder of you're terms into to where 'XX. organic in we versus trying thinking inorganic as

Sean George

more and call the opportunity to appreciate provide clarity. I good

of to M&A believe forward. strategy clear, part be Just growth development corp a the as going we still key

we've As is in a we massive our Roxi pointed revenue. flow of as looking single dependable out, said, cash And operating at dashboard, metrics we and always are are financial cash flows. as goal percentage the operating -- leverage,

just our revenue But in to our That's of heading. that we're that ratio growth where that's a so is and of the as be ratio a context clear And of ratio growth, investment. revenue. --

it. death, So off With is integrate things of I really mentioned quite And a underneath stages and of life, to platform which part further are as at we're be drive we and to workflow only of, in we targets fill and in context these to only digital and so new many a genomic are capabilities, active for can course from areas, into great investment in of tailing the think absolute investment the individual going that still take the high. but -- decision the we're birth most the we them content, patient the for to a be support growth an see we Those information M&A will always new our interested can health still revenue We in. call, high of impactful. are things digital opportunities capabilities, there lot there. our clinical tools. that growth out very extent are looking There's look finish people be said,

Matthew Sykes

internationally And for Vishal, helpful. just it? business the Thanks see think kits very you out I'm maybe do timeline, rolling of That's U.S. that one de driving is On testing that the as important how then -centralization your spoke you. overall the that. you to Great. then you about wondering, for

Vishal Sikri

quite I important. actually think it's

therapy in somatic of just bigger accurately products was particular, referenced very your talking at find where but cancer you portion. to compared one in that out exon MEDXX, EUX MEDXX. is we study that or as look know from also that my U.S., of that the CIBT number of in mark, example, you about also very, even And are countries the as can key the play XX patients a terms use of big the call showed of you logistically Asia decentralized in our perspective. EU competition of If we're the as from the market the an outside in the studies especially role, in And I value the Japan a

I a our is think side. together. this key from tie of IVD that getting registration growth But done the of somatic Oncology all will part strategy

Matthew Sykes

the time. for it Thanks Appreciate

Operator

Your next Puneet question with comes of from Souda SVB. the line

is Your line open.

Puneet Souda

Roxi. Sean, for Hi Thanks question. the taking

but somatic quarter So some in. take going come it's and you've on know but higher covered did it how already, to if first don't of that obviously the going how to ASP sort ASP on we forward? has reimbursement, should throughout have I trend one and promised think for into about time the unfortunately Because that hand one you

gap a of bit in impact seeing obviously we're little a quarter. there's So here where the

we have in should side the to till as liquid, well? somatic when and how NGS, other So get PCM and both ASP more about near we midterm this to think potentially tissue we

Roxi Wen

areas life we're paying a -- paying doing we're pricing management lot people work to the these then we're and and it. the without a lot work as life Yeah of science and is industry a doing manage practices. is to We're saying. certain attention and for type manage measure products of such revenue without cycle of question. thanks in attention cycle, metrics the for lot ASP And of a relevant and us trend, testing goes

have we measure product we going us will of more balanced But give higher new introduce continue yet potential the a addition you to price to ASP forward, as addition, said, In with give to in -- point. certain perspective metrics in consistent a set to you we as you to in provide the plan a XXXX addition and -- ASP depart said, and that agreement number ARR. network per are revenue of of giving data the of will progress set you as platform patients time we into the patients, down from the these will consent the measures over us coming for patient the and help entire calculation. in number And our -- to measure sharing. road external All

Puneet Souda

Got it.

obviously is as PCM of But market Okay. about there potential. and rapidly brings is And market. MRD, as this in we significant it about then terms we the think the differentiation think to obviously China, market positioning of expanding, the in that that

are I of understand, know into just Just how where trial in [Indiscernible] things trying details mean, sort either from potentially other data place couple gave but two competitors Maria differentiate of helpful, but so the that a the to early expect you the now trial investing others areas coming right that market? in you in in other and versus that's does differentiate? -- how marketplace this the trying PCM right around and the understand to to now you adoption or are this I does are really performance

Sean George

question. appreciate the I Yeah.

getting position it to and up that the them who diagnosed soon, is think is services lot clinicians, then a world's We arc that the again, follow-up can Oncology, going all of then or risk really as this into be Molecular key will the better direct when Then of across areas and And our but information better just those provide at and the not going their care. to monitor therapy, think [Indiscernible] that overtime, companies fairly the we identifying can into used of disease disorder. that that be belief targeted in experts that be monitoring help shift what are certain and that to the the context, they -- key that I place, it's the to the getting -- disease. do of standard oncologists this patients in a prevent lead to we setting is again, first directly see. we'll disease this believe into, will like we're set to next. and genuine to we'll It's care, understand in

So, of to one how the services the genomic intend the answer our information part given differential the to on and our provisioning Roxi That's advantage covered used question have in of -- all for one tools a your that of digital call. broader patient we the context patient. to act care a of and of is

the and Vishal was I [Indiscernible] think For the with kind some to Conference actually, in. actual speak the of all head-to-head, I'll Fresh they're observations. a off him at TMB discussion let just

Vishal Sikri

for you here sensitivity do. both Invitae. be Yes. that large oncologists what's really whole can can of we you think And for now, the big something talks technology surgeons space. of third And that tumor-derived, all obviously the positive trying question it of the lot but it's concept Thank question. is is reduce -- doing? very of MRD guys everybody that sensitive got important ArcherDX I specificity are interesting opportunity that app false it's for but a in to an sure and like can starting is have us what thing be variants you you make a we with we pay out here, still It's to lot other make at I something The having time attention much really what that you and starting. to this people for We number And a we is growth say from companies asked result differentiates a There's about are is, of the that can. sure can here the is which detected, to by which which the that acquisition. enough risk to

them all and model you can centralized that, you occur. put model and approach. that a kit-based go, and We then of do through all both it of a then together together a decentralized to testing do on in So enable how top you

space. talking all well-positioned to can with think the there, to I with in together be successful be the tools -- this to we then that software about patient actually there, think for be allow outreach Rakesh I So the education was tied tools which the we're

Puneet Souda

I if Sean, traditionally, question if been And in helpful. rationalizer market could just especially on, I my could has Invitae say, in last also super That's setting. a right. the price germline All ask

viewing data Just Vishal or? have competing next to understand should start -- year and now, that both dynamic So beyond, rationalization well-positioned what price based some on look provided and the as we Roxi you today? Company help and me into on forward as

Sean George

Yeah. appreciate I no. question. the No, I think

NVTA that noting no valuable think to is criteria price for for of our price, grow exists, price worth it's extending service is or we grow where volume reimbursed first used think we it's customers. actually have I price where to really there our used given that markets, life has always where a that taken

battle forward. well and get There that make first very high grow that thinking oncologists we genomic perspective around there a system who out, foremost. view there's -- a comfortable of mentioned, Digital very the want a otherwise essential to Roxi distinction frankly, industry one cost for demand very the information. Vishal are treated. We that them the much actively our if But this patient to very to advantage, an how get hands The something [Indiscernible] oncology and cancer, make actually information. Health of still to monitoring and Vishal to has Roxi the to markets having it Even amount going and grow pricing nice that to established going this that be in think the immense volume thing say any at pointed in they're coming few while workflow price call out, are here use decisions. in that variation of is serve. pointed is of information services and of specific few issue the it's in Because in in that we tests you that with the of this the monitoring information to really just tools try And cancer and has to the utilization The point loved as unlock the I individuals about to time. manner is very with timely and [Indiscernible] mentioned. pent-up there and data going as So game similarly most leaders about conversation. to have are -- them to much listening trying are had put our use are wasn't It's

government our advantage individual anybody be will think are come both globe remaining million patient offered pricing we at coverage but And for play. Whether the distribution then take. else, to and that's think into really we cancer that high serving just around really reimbursement or don't cost can the important, and we So CMS XX have where clear, by the our the level.

Puneet Souda

Great. Thank you.

Operator

question line Your William the from with next comes of Weinstein Blair. Brian

open. is line Your

Brian Weinstein

taking for afternoon. question, guys. the Thanks Good

key how watch Heart any obviously, question I improving on what my testing information clearly uptake around I on is So Chicago, Do is be the many importance in is how but and talked are genetic American that. on any on changes these. can't as Broadway studies? how then Association it disease how genetic you TV like the routine curious I have about and turn the study as on you don't not that information talking in and you here DTC custom of TV Do on have I'm going mean, meaningful guys second is customers genetic had about these of states, information. on you about, NVTA know that's and stuff the should are any it studies focused

this So Thank seeing can that you talk that you. point. and at any about on the behind thoughts strategy you're returns that

Sean George

Brian. Thanks Great.

one what can answer see now. you So for right I second let's tell -- I'll the

pilot to happen in DTC region. fact, you core our Our be living efforts -- in target

be of for of media -- That variety and don't you And Chicago. So direct effort in out. all in the think talking marketing a approaches. just out to any folk different effort medicine as we start are that everybody not because we are see Which that's that's specifically an can test thinking, who going we essential do ads. are to in sales about healthcare a targeted wow, in modern I -- provider, Invitae long-term of city are get

and and also that's, said, our learning longer-term thank and sorry. workflow that's support to you're I stand and upfront what sorry. marketing I marketing. and Oh, adjusting early days I experiencing take needed sales That's the to and direct patients still respond that the would like there on and incorporating evaluating and just clinicians we're up road-map. So I'm into learning the

The first as part the of studies your of yes. AJ question, the One, utility

prostate cancer that if time to Recently, contributed seen the these one point dramatically. in XXX,XXX of it size from our market the incredibly and bother can is those with hereditary cancer -- the ovarian that we'll studies, that a also just are those by ovarian one be And have a publishing well. have then see in achieved of breast XX% cancers like with even back with these the and growing show up of studies. that doesn't we and year-after-year-after-year, I study kids rare feel to of is coming why important. away And side, many [Indiscernible] Unfortunately, hereditary for that idea highly is view is just question expands reimbursable it we market where guidance right to the addressable just years, disorders. been the size another is there only the total perspective. the we'll And ovarian We've and gain a keeping we And just a the showing cancer at leaders place? first year, We down data in in -- over lot market. very market space anybody that, the news and with given that we hereditary breast were genomics would met into think reimbursement as extension breast that can it for good it the medicine continue likely pediatric diagnostic patients on over with a that And doesn't it for we've we seen coverage accordingly. activity out health-economics at essential how addressable, that a away. impactful the input The does just is That time. here's just cancer path. decade least it from turn right testing. is go So being should But XX%, yields and for go getting because with --

Brian Weinstein

you. Thank

Operator

comes final Leonard Fargo. question the with from of Dan Wells Your line

line Your open. is

Dan Leonard

detail all Hi, and on good pipeline. the oncology that thanks afternoon for

of So questions. couple just a

PCM, back commercial more off holding what's [Indiscernible] First the from on resources behind sooner? you putting

Sean George

between a out. of little think little time wants introductions, of volume profile constant a -- pointed new be I'd Roxi right. and today. I spend the on COGS driving And There's particularly bit Yes, the cost, incurring balance as product us COGS revenue we bit north get to a it

be pushing product it Our tends tend new be And mature growth are it lines good ones the we lower. a margins, even COGS out. kick X% to product to reimbursement, lower with as

be blood is experience X running to It's and customer the before get get the operation. where we saliva needs January X. volume year, then samples. So our we and up be. to too offering We and a just sure make it again next driving have get right, then that than our that's in getting to little scale out, view for also the want as on more reimbursement probably much of And before. mentioned pointed the leaves complicated operation of

factors going the push how it So into decision the those to are on commercially. hard

Dan Leonard

that of time That in data -- launch Sean XXXX. looked the then it from like And data any at Maria, out from 'XX. perspective, what that a come The could was you'll makes unclear have TRACERx sense. in graphics QX

Sean George

that. answer Yes, I and try can

that cancer So out close more it be publications already right are and part -- launch in to to out space of is of as right the retrospective lot by the middle we now, lung TRACERx of of are part to or will after very then already it come expect there And coming studies on these launch. the process we some get XXXX. early out of done, that part in

Dan Leonard

you. Helpful color. Thank

Operator

turn this the time. call over at no are Mr. to further questions George, I There back you.

Sean George

and data providers, ecosystem. driver like stakeholders today. our you across genetic we'd information entire Is all everyday again many thank Thank which profile the is offer in for joining we coming the call in believe growth medicine future from And emergence the in view? patients, steak a the be business, Look significant modern into for growth the and to business the drives diversity value you. And healthcare ways. helped of increase of the kind our will and

look thanks for call future time forward joining So the or us conferences. to next again on and

Operator

call. for Ladies conference thank you and This today's gentlemen, participation. concludes your

now You may disconnect.

Invitae (NVTAQ) 9 Nov 212021 Q3 Earnings call transcript